In the BioHarmony Drug Report Database

"Preview" Icon

Fosaprepitant dimeglumine

Emend, Fosaprepitant Dimeglumine, Ivemend (fosaprepitant dimeglumine) is a small molecule pharmaceutical. Fosaprepitant dimeglumine was first approved as Emend on 2008-01-11. It has been approved in Europe to treat neoplasms and vomiting. It is known to target substance-P receptor.

 

Trade Name

 

Ivemend
 

Common Name

 

fosaprepitant dimeglumine
 

ChEMBL ID

 

CHEMBL1201782
 

Indication

 

neoplasms, vomiting
 

Drug Class

 

Tachykinin (neurokinin) receptor antagonists: NK1 receptor antagonists; phosphoro-derivatives

Image (chem structure or protein)

Fosaprepitant dimeglumine structure rendering